Bachem Holding (BANB) Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BANB Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 58.75 |
| 52 Week High | CHF 77.60 |
| 52 Week Low | CHF 43.34 |
| Beta | 0.84 |
| 1 Month Change | 0.43% |
| 3 Month Change | -15.16% |
| 1 Year Change | -14.05% |
| 3 Year Change | -17.02% |
| 5 Year Change | -24.49% |
| Change since IPO | 319.64% |
Recent News & Updates
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Oct 25
Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
Aug 16Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues
Jul 30Recent updates
Bachem Holding AG's (VTX:BANB) Price In Tune With Earnings
Oct 25Bachem Holding (VTX:BANB) Ticks All The Boxes When It Comes To Earnings Growth
Sep 18Bachem Holding (VTX:BANB) Seems To Use Debt Quite Sensibly
Aug 16Bachem Holding's (VTX:BANB) Profits May Not Reveal Underlying Issues
Jul 30Bachem Holding AG's (VTX:BANB) P/E Is Still On The Mark Following 28% Share Price Bounce
Jul 25Bachem Holding AG's (VTX:BANB) Share Price Matching Investor Opinion
May 15Some Shareholders May Object To A Pay Rise For Bachem Holding AG's (VTX:BANB) CEO This Year
Apr 24Bachem Holding (VTX:BANB) Will Pay A Larger Dividend Than Last Year At CHF0.85
Apr 11
Building K And 24-Hour Operations Will Improve Efficiency
Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides.What You Can Learn From Bachem Holding AG's (VTX:BANB) P/E
Dec 29Here's Why We Think Bachem Holding (VTX:BANB) Is Well Worth Watching
Nov 10Shareholder Returns
| BANB | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | 2.1% | -2.6% | -1.4% |
| 1Y | -14.0% | -3.9% | 4.2% |
Return vs Industry: BANB underperformed the Swiss Life Sciences industry which returned -3.5% over the past year.
Return vs Market: BANB underperformed the Swiss Market which returned 2.5% over the past year.
Price Volatility
| BANB volatility | |
|---|---|
| BANB Average Weekly Movement | 4.4% |
| Life Sciences Industry Average Movement | 4.4% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 1.7% |
Stable Share Price: BANB has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: BANB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,292 | Thomas Meier | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BANB fundamental statistics | |
|---|---|
| Market cap | CHF 4.40b |
| Earnings (TTM) | CHF 134.19m |
| Revenue (TTM) | CHF 677.93m |
Is BANB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BANB income statement (TTM) | |
|---|---|
| Revenue | CHF 677.93m |
| Cost of Revenue | CHF 466.24m |
| Gross Profit | CHF 211.69m |
| Other Expenses | CHF 77.50m |
| Earnings | CHF 134.19m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 12, 2026
| Earnings per share (EPS) | 1.79 |
| Gross Margin | 31.23% |
| Net Profit Margin | 19.79% |
| Debt/Equity Ratio | 4.5% |
How did BANB perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/30 02:46 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bachem Holding AG is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantin Wiechert | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |
| Leonildo Delgado | Baader Helvea Equity Research |